Navigation Links
Cipralex demonstrates superiority to duloxetine for acute treatment,of depression in new study

COPENHAGEN, June 4, 2007-A new study published today in the journal Current Medical Research and Opinion showed that Cipralex® (escitalopram) was superior to Cymbalta® (duloxetine) in the acute treatment of patients with major depressive disorder (MDD) and was at least as efficacious in long-term treatment. The study directly compared Cipralex® (an allosteric serotonin reuptake inhibitor - ASRI) to duloxetine (a serotonin and noradrenaline reuptake inhibitor - SNRI) and also demonstrated that Cipralex® was better tolerated, with fewer patients discontinuing treatment with Cipralex® due to adverse events compared to duloxetine.

Depression is a serious illness that results in significant disability and is associated with both increased morbidity and the risk of suicide. Affecting around 121 million people globally, the World Health Organization lists depression as the leading cause of disability worldwide.

"Cipralex® is an effective and well-tolerated drug for the treatment of depression and a wide range of anxiety disorders," said Senior Vice President Anders Gersel Pedersen, Head of Development at Lundbeck. "These new data provide further evidence of the strong efficacy and tolerability profile of Cipralex® compared to other antidepressants in the treatment of depression."

About the clinical study The study was designed to look at the efficacy and tolerability of Cipralex® compared to duloxetine in patients with moderate to severe MDD over 24 weeks, with a secondary endpoint at eight weeks (acute treatment).

The double-blind, fixed-dose, comparative study included 294 patients with MDD from 35 centres in nine countries. Patients were randomised to either Cipralex® (n=143) or duloxetine (n=151), at dosing regimens currently recommended in the package inserts in participating countries (Cipralex® 20mg, duloxetine 60mg).

Patients were evalu
'"/>




Page: 1 2 3

Related medicine technology :

1. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
2. Amsterdam Molecular Therapeutics BV to present preclinical proof-of-concept data on its gene therapy AMT-020 to treat acute intermittent porphyria
3. Liraglutide provides significantly better glucose control than insulin glargine in phase 3 study
4. First single breast cancer study to show significant survival benefit for women switching from tamoxifen to Arimidex
5. Positive results from placebo-controlled phase IIa study in patients suffering from house dust mite allergy
6. 2007 ASCO Annual Meeting: Clinical Results on Phase IIb-study with AP 12009 in Anaplastic Astrocytoma selected for Poster Discussion
Post Your Comments:
(Date:12/15/2014)... Dec. 15, 2014  Inovio Pharmaceuticals, Inc. (NASDAQ: ... been added to the NASDAQ Biotechnology Index (NBI). ... become effective upon market open on December 22, ... designed to track the performance of a set ... biotechnology or pharmaceutical according to the Industry Classification ...
(Date:12/15/2014)...  Stephen Squires, CEO and founder of leading North ... (OTCQB:QTMM), will be speaking at the launch event for ... 16th, 2014. The RCQM launch continues Rice University,s leadership ... faculty and students and by inviting the world,s leading ... "We have a long association with Rice University ...
(Date:12/13/2014)... 11, 2014 Research and Markets ... the "Drug Injection Devices to 2020" ... http://photos.prnewswire.com/prnh/20130307/600769 As new drugs ... list of health conditions, drug developers have increasingly ... administration process and increase the efficiency and reliability ...
Breaking Medicine Technology:Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 2Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 3Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 4Quantum Materials CEO Stephen Squires to Speak at Rice Center for Quantum Materials Launch 2Quantum Materials CEO Stephen Squires to Speak at Rice Center for Quantum Materials Launch 3Drug Injection Devices to 2020 2Drug Injection Devices to 2020 3Drug Injection Devices to 2020 4
... UPI ) announced today that it will release financial ... at the market close on Monday, November 2, 2009. ... results on Monday, November 2, 2009 at 3:30 p.m. Central ... Medi Jiwani, Vice President, Chief Financial Officer and Treasurer, will ...
... 21 Shire plc,(LSE: SHP, NASDAQ: SHPGY ), ... Biologics License Application (BLA) with the U.S.,Food and Drug ... for Fabry disease, by the end of the year. ... filed at the,request of FDA, has been approved, and ...
Cached Medicine Technology:Uroplasty to Issue Second Fiscal Quarter Results on November 2, 2009 2Shire Targets Fourth Quarter Filing of BLA for REPLAGAL(R) for Fabry Disease With U.S. FDA 2Shire Targets Fourth Quarter Filing of BLA for REPLAGAL(R) for Fabry Disease With U.S. FDA 3Shire Targets Fourth Quarter Filing of BLA for REPLAGAL(R) for Fabry Disease With U.S. FDA 4
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
(Date:12/15/2014)... News) -- Expert pilots process visual information more efficiently ... better decisions during landings, a new study shows. ... pilots to master, and 36 percent of all airplane ... final approach and landing. Researchers monitored the brain ... pilots while they were at the controls of a ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
... The Department of Health will hold a series of ... are ready for the current influenza pandemic and the ... this fall. , , "The World Health Organization,s ... of having a solid, functional pandemic plan in place," ...
... say, , TUESDAY, June 30 (HealthDay News) -- People who ... radiation in order to obtain usable X-ray images, even though ... need to get a certain amount of X-rays to go ... and excess weight impedes that," explained the study,s lead author, ...
... stressful and can pose health threats to caregiver givers. Steven ... Studies, Penn State, received a $3 million grant from the ... on familial caregivers. He will look at people who care ... impacts the stress levels of all individuals involved. People with ...
... Entrepreneurial Excellence and Community Improvement , , MINNEAPOLIS, ... part of Experian and a leader in financial clearing ... Daniel Johnson, received the Ernst & Young Entrepreneur Of ... the Upper Midwest region. According to Ernst & Young ...
... NASHVILLE, Tenn. and COLUMBIA, S.C., June 30 Informatics ... Companion Data Services, LLC (CDS) to offer a solution ... to create a unified electronic health record. ICA and ... the capability to electronically move clinical information among disparate ...
... its first NDA - AllerNaze(TM) , , BSE: 500257 ... , , MUMBAI, India, June 30 Pharmaceutical Major, ... the intra-nasal steroid (INS) product, AllerNaze(TM) (triamcinolone acetonide, USP) Nasal ... United States will be the first market in which Lupin ...
Cached Medicine News:Health News:Pennsylvania Department of Health Workshops Will Help Businesses Prepare for Flu Pandemic 2Health News:Obese Get Higher Doses of Radiation for X-Rays 2Health News:Obese Get Higher Doses of Radiation for X-Rays 3Health News:Caregivers may benefit from adult day care 2Health News:SearchAmerica(R) President, Daniel Johnson, Named Ernst & Young Entrepreneur Of The Year(R) 2Health News:SearchAmerica(R) President, Daniel Johnson, Named Ernst & Young Entrepreneur Of The Year(R) 3Health News:ICA, CDS Team Up to Offer Solution That Aggregates Patient Information 2Health News:ICA, CDS Team Up to Offer Solution That Aggregates Patient Information 3Health News:Lupin Expands Branded Play 2Health News:Lupin Expands Branded Play 3
... Special Low-profile Hourglass Jaw Design ... Through A Minimal Incision.,Mirror Polished Blades ... Acting Handle Mechanism Offers Control Over ... Prevent The Lens From Tilting During ...
... Opening Is Designed To Pinch And ... A Separate Cystotome. The 11mm Jaws Are Formed,To ... Incision.,The Distal Jaws Have Platforms, And The Proximal ... Pick Up Of Iris. The Unique Jaw Structures ...
2.5V Halogen source, fiber-optic delivery, 3X magnification, pocket-sized....
... offer patented Sensomatic® handles that ... up and switch off when ... of light from 2.5V halogen ... of examination area. Used ...
Medicine Products: